A

AcelRx Pharmaceuticals Inc
F:R5X

Watchlist Manager
AcelRx Pharmaceuticals Inc
F:R5X
Watchlist
Price: 2.106 EUR 9.74% Market Closed
Market Cap: 310.3m EUR

Operating Margin

-3 753%
Current
Improving
by 1 688.7%
vs 3-y average of -5 441.7%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-3 753%
=
Operating Income
$-20m
/
Revenue
$620k

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-3 753%
=
Operating Income
€-20m
/
Revenue
$620k

Peer Comparison

Country Company Market Cap Operating
Margin
US
AcelRx Pharmaceuticals Inc
F:R5X
310.3m EUR
Loading...
US
Eli Lilly and Co
NYSE:LLY
982.2B USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
524.3B USD
Loading...
CH
Roche Holding AG
SIX:ROG
273.4B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
208.3B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
270.2B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.7B USD
Loading...
No Stocks Found

Market Distribution

Lower than 95% of companies in the United States of America
Percentile
5th
Based on 14 112 companies
5th percentile
-3 753%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

AcelRx Pharmaceuticals Inc
Glance View

Market Cap
310.3m EUR
Industry
Pharmaceuticals

AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. The company is headquartered in Hayward, California and currently employs 43 full-time employees. The company went IPO on 2011-02-11. The firm is focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio of products and product candidates consists of sufentanil sublingual products and product candidates, pre-filled syringe product candidates and nafamostat mesylate product candidates. Its sufentanil sublingual products include DSUVIA, DZUVEO and Zalviso, which are focused on the treatment of moderate-to-severe acute pain in a medically supervised setting. Its pre-filled syringe product candidates include Ephedrine and Phenylephrine. Its nafamostat mesylate product candidates include Niyad, which is a regional anticoagulant for injection into the extracorporeal circuit, and LTX-608, which is a nafamostat formulation for antiviral treatment of COVID, acute respiratory distress syndrome (ARDS), disseminated intravascular coagulation (DIC), and acute pancreatitis.

R5X Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-3 753%
=
Operating Income
$-20m
/
Revenue
$620k
What is AcelRx Pharmaceuticals Inc's current Operating Margin?

The current Operating Margin for AcelRx Pharmaceuticals Inc is -3 753%, which is above its 3-year median of -5 441.7%.

How has Operating Margin changed over time?

Over the last 3 years, AcelRx Pharmaceuticals Inc’s Operating Margin has decreased from -1 061.1% to -3 753%. During this period, it reached a low of -11 813.9% on Mar 31, 2023 and a high of -725.3% on Mar 31, 2021.

Back to Top